US FDA seeks input on nanotechnology guidelines
This article was originally published in Scrip
Executive Summary
The US FDAwill gather public comments and data at a September 8th meeting to aid the development of guidelines for nanotechnology products. Last year an agency task force report recommended development of various guidance documents on the use of nanoscale materials (Scrip Online, July 26th, 2007). These included guidelines for sponsors on identifying the particle size for drugs and biologicals, and for submitting information on how nanoscale materials affect the manufacturing process. The meeting's primary purpose is to determine what factors the FDA should consider in providing guidance on the information and data needed to demonstrate safety and effectiveness of products containing nanoscale materials, and the circumstances under which a product's regulatory status might change owing to the presence or use of nanoscale materials.
You may also be interested in...
Keep Makena Under Accelerated Approval Pending More Studies, AMAG Tells US FDA
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
2020 In Review: US FDA New Drug Office’s COVID-19 Response Aided By Reorganization
Office of New Drugs Director Peter Stein tells the Pink Sheet that last phase of massive reorg was complicated by pandemic restrictions that forced review staff to work remotely, but the structural overhaul resulted in smaller, more nimble review groups and the breaking down of silos that ultimately helped the agency’s response to the public health crisis.
Postmarketing Safety Gets Closer Focus In Latest US FDA Drugs Center Reorganization
Division of Mitigation Assessment and Medication Error Surveillance will be established within the Office of Surveillance and Epidemiology, a change aimed at strengthening postmarketing oversight of opioids and other drugs; new Office of Safety and Clinical Evaluation will be created in Office of Generic Drugs, where Orange Book staff also will get their own division.
Need a specific report? 1000+ reports available
Buy Reports